Hypoxia Inducible Factors (HIFs) are critical mediators of the cellular response to decreased oxygen tension and are overexpressed in a number of tumors. While HIF1α and HIF2α share a high degree of sequence homology, recent work has shown that the two α subunits can have contrasting and tissue-specific effects on tumor growth. To directly compare the role of each HIFα subunit in spontaneous tumorigenesis, we bred a mouse model of expanded HIF2α expression and Hif1α +/− mice to homozygotes for the R270H mutation in p53. Here we report that p53 R270H/R270H mice, which have not been previously described, develop a unique tumor spectrum relative to p53 R270H/− mice, including a high incidence of thymic lymphomas. Heterozygosity for Hif1α significantly reduced the incidence of thymic lymphomas observed in this model. Moreover, reduced Hif1α levels correlated with decreased stabilization of activated Notch1 and expression of the Notch target genes, Dtx1 and Nrarp. These observations uncover a novel role for HIF1α in Notch pathway activation during T-cell lymphomagenesis.
Introduction
Hypoxia, or decreased oxygen (O 2 ) availability, is a common characteristic of solid tumors. Cells have developed a number of adaptive responses to O 2 deprivation that are largely mediated by the Hypoxia Inducible Factors (HIFs). HIFs function as αβ heterodimeric transcription factors that regulate over 150 genes involved in metabolism, cell cycle regulation, erythropoiesis, cell survival, and angiogenesis (1, 2) . The β subunit is constitutively expressed, while the stability of the three α subunits is regulated by O 2 availability. Two HIFα subunits, HIF1α and HIF2α, have drawn considerable interest since their discovery. HIF1α and HIF2α share a high degree of sequence homology but display distinct expression patterns in the adult organism. HIF1α is expressed ubiquitously in the adult, while HIF2α expression is restricted to the endothelium, kidney, heart, and lung (3) (4) (5) . In addition, the two subunits have both shared (such as Vegf) and unique transcriptional targets. For example, HIF1α exclusively regulates glycolytic enzymes, whereas HIF2α preferentially regulates genes involved in differentiation (Oct4) or proliferation (Epo, Tgf-α) (6) (7) (8) .
The observation that HIF1α and HIF2α are highly expressed in a number of human tumors fueled early studies to evaluate the role of each subunit in tumor initiation and progression. Previous attempts to explore the role of HIFs in tumorigenesis utilized subcutaneous models in immunocompromised mice. When injected into mice, transformed Hif1α −/− mouse embryonic fibroblasts grow more slowly and form less vascularized tumors than wild-type fibroblasts, suggesting a role for HIF1α in both tumor growth and angiogenesis (9) . In contrast, HIF2α appears to promote the growth of human neuroblastoma and renal clear cell carcinoma tumors in nude mice, whereas HIF1α does not (10) (11) (12) (13) (14) . Furthermore, HIF2α actually inhibits tumor growth and promotes apoptosis in rat gliomas (15) . These studies suggest that the two HIFα subunits have distinct effects on tumorigenesis. They also indicate that either the HIFs have tissue specific functions or that xenografts do not accurately replicate the microenvironment for tumor formation in vivo. Introduction of established tumor cell lines subcutaneously in nude mice assesses the capacity of these cells to proliferate and stimulate angiogenesis, but does not evaluate tumor initiation, progression, and metastasis, or the effects of the local microenvironment on tumor growth. A recent study by Liao et al. in a mouse breast cancer model demonstrated that HIF1α is not necessary for tumor initiation, but HIF1α loss results in increased tumor latency and decreased proliferation, angiogenesis, and metastatic potential (16) . Since HIFα effects are likely to be tissue-and tumor stage-specific, studies in spontaneous tumor models will be critical to determine the role of each HIFα subunit in cancer.
To this end, we employed our previously described "knock-in" mouse model in which the HIF2α coding sequence is under the control of the Hif1α locus (Hif1α KI/+ ), thereby broadening HIF2α expression to all tissues (6, 17) . In fact, HIF2α has been detected in tumors derived from tissues in which it is not normally expressed (18) . This genetic manipulation not only allows us to compare the effect of each subunit directly, as they are expressed in the same tissues, but also avoids non-specific effects from dramatic overexpression encountered in some transgenic models. Homozygous Hif1α KI/KI embryonic stem cells generate more proliferative and vascularized teratomas than their wild-type counterparts, further supporting a role for HIF2α in promoting tumor growth (17) . Unfortunately, Hif1α KI/KI mice die before embryonic day 8.5, precluding their use in a tumor study, but heterozygotes are viable (6) . Since adult Hif1α KI/+ animals do not develop tumors spontaneously (M.C. Simon, unpublished), we induced tumor formation by crossing them to mice bearing an arginine to histidine mutation in codon 270 of p53 (p53 R270H ) (19) . The equivalent human mutation (R273H) is commonly detected in patients with Li-Fraumeni syndrome, where patients develop a wide range of tumor types at a young age (19) . In contrast to null p53 mutations, R270H mutants develop carcinomas in a number of tissues, suggesting that mutant p53 possesses gain-of-function effects in a tissuespecific manner (20) (21) (22) . To further accelerate tumorigenesis, we generated p53 R270H/R270H (referred to as p53 H/H ) mice, which have not been previously characterized. To determine whether HIF2α could promote tumorigenesis in certain tissues, we evaluated three cohorts with varying HIFα expression for tumor spectrum and onset ( Figure 1A) 
Materials and Methods

Aging Study
Cohorts were produced by mating p53 H/+ mice to p53 H/+ or p53 +/− mice. Since the p53 H/+ mice were enriched for 129S 4 /SvJae (19) , the p53 −/− allele was in a mixed C57BL/6-129/Sv background (23) , and Hif1α +/− and Hif1α KI/+ mice were 129SvEvTac enriched (6) , all mice were of a similarly mixed background. Mice were evaluated daily for signs of morbidity or tumor growth. Distressed mice were euthanized by CO 2 asphyxiation and dissected. All soft tissues were fixed in 4% paraformaldehyde and processed as previously described (19) . Tumors were then identified by veterinary pathologists (A.C.D. and M.H.G.).
Immunohistochemistry (IHC)/Immunoblotting
IHC was performed following manufacturer's guidelines and developed using diaminobenzidine (DAB, Vector Labs, Burlingame, CA). Primary antibodies used in this study are listed in the supplement. TUNEL staining was performed using the ApopTag Peroxidase In Situ Apoptosis Detection Kit (Millipore) as per manufacturer's instructions. Positivestaining cells were counted in 8-9 fields per tumor using ImageJ (NIH). Standard techniques were employed for immunoblotting.
RNA extraction and QRT-PCR
Tissues were stored in RNALater (Qiagen). For RNA extraction, tissues were homogenized in Trizol (Invitrogen) and purified using Qiagen RNeasy columns. cDNA synthesis was performed as described previously (24) . Taqman primer/probe sets were purchased from Applied Biosystems (Foster City, CA). Microarray analysis was performed at the University of Pennsylvania Microarray Core using the Affymetrix MOE430Av2 array. Raw data for expression profiling are available through the NCBI Gene Expression Omnibus (GEO) with the accession number GSE14336.
Sequencing
The PEST domain of Notch1 was amplified for sequencing from cDNA using the following primers: 5′-TACCAGGGCCTGCCCAACAC-3′, 5′-GCCTCTGGAATGTGGGTGAT-3′, and 5′-AAGGACCTCAAGGCACGGAG-3′ 5′-GAGGTGTGGCTGTGATGGTG-3′ (25) .
Results
Generation of tumor prone mice with expanded expression of HIF2α
To assess the effect of HIF2α on spontaneous tumorigenesis in vivo, we crossed Hif2α knockin (Hif1α KI/+ ) mice (17) with p53 H/+ animals (19) which are prone to spontaneous tumor formation. As a control for loss of one Hif1α allele, we crossed Hif1α +/− mice to the same p53 mutant strain. To generate mice homozygous for the R270H mutation and either wild-type for Hif1α (Hif1α +/+ ) (n=23), heterozygous for Hif1α (Hif1α +/− ) (n=20), or carrying an additional Hif2α allele (Hif1α KI/+ ) (n=24), we intercrossed heterozygotes for the R270H mutation from each Hif1α genotype ( Figure 1A ). The Hif1α KI/+ animals were generated in the 129SvEvTac background; therefore, Hif1α +/− mice were backcrossed into the 129SvEvTac strain to control for strain differences (6) . Successful generation of each cohort was verified by PCR on tail DNA within the first weeks after birth ( Figure 1B ) and confirmed by repeating all four PCRs on tail DNA after animal sacrifice (Embark Scientific). To quantify HIF2α expression in normal Hif1α KI/+ tissues, QRT-PCR for HIF1α and HIF2α was performed on duodenum and skeletal muscle samples taken from Hif1α +/+ , Hif1α +/− , and Hif1α KI/+ mice on a wild-type p53 background ( Figure 1C ). As expected, Hif2α mRNA levels were increased in normal tissues. Given that our mouse model is one of expanded HIF2α expression and not HIF2α overexpression, these changes (~2 fold) were in the expected range and were similar to levels measured in Hif1α KI/+ embryos (6).
Dosage of the p53 R270H mutation affects tumor spectrum
Upon dissection, each mouse organ was fixed and prepared for histological analysis, which was conducted by a board-certified veterinary pathologist (A.C.D.). Since the tumor spectrum in mice homozygous for the R270H mutation had not been previously examined, we compared tumor incidence in p53 H/H (n=23) mice with p53 H/− (n=19) animals in a Hif1α +/+ background. Interestingly, p53 H/H mice developed substantially more thymic lymphomas (p=0.0015) and tended to present with these tumors at an earlier age than mice in the p53 H/− cohort, although the age difference was not statistically significant (Figure 2A-B) . Instead, p53 H/− mice developed sarcomas (p=0.03), brain tumors and teratomas. Why carcinomas (as described by Olive et al. (19)) were not observed in our p53 H/− cohort is unclear, but may be due to subtle changes in growth conditions provided by different animal barrier facilities. Gross and histological findings are provided in Supplemental Figures 3 and 6. The incidence of thymic lymphomas in the p53 H/− cohort was consistent with published studies (19). Our p53 H/H mice were generated in the 129S 4 /SvJae background (19), a strain less susceptible to lymphomas than C57BL/6 (26) . By contrast, the p53 −/− mice were of a mixed C57BL/6-129/Sv background (23) , which should increase their tendency to develop thymic lymphomas (see Materials and Methods). Thus, the higher incidence of lymphomas in p53 H/H mice is likely to be a specific effect of the mutant allele.
As noted previously in p53 H/+ mice (19), we observed the accumulation of mutant p53 protein by immunohistochemistry on tumor sections obtained from p53 H/− and p53 H/H animals ( Figure  2C ). The dramatic increase in thymic lymphoma incidence in p53 H/H mice indicates that gainof-function effects of mutant p53 protein may uniquely or more potently impact thymocytes. Both the increase in number and decrease in age of onset of thymic lymphomas in the p53 H/H cohort further suggest that the R270H is not simply a loss-of-function allele.
Loss of one Hif1α allele reduces the incidence of thymic lymphomas detected in p53 H/H mice Hif1α +/+ p53 H/H mice exhibited an abrupt decrease in survival between 100 and 130 days ( Figure 3A ). These animals were sacrificed due to obvious signs of respiratory distress and displayed large thymic lymphomas upon dissection. Hif1α KI The age at sacrifice for all tumors combined ( Figure 3B ) and tumor burden ( Figure 3C) were not significantly different between genotypes; however, careful gross and histological analysis of each mouse tissue revealed differences in tumor spectra (Figure 4, Supplemental Figure 1 ). Hif1α +/+ p53 H/H mice exhibited ~30% more CD3 + thymic lymphomas ( Figure 3D, 4 Figure 3D , Supplemental Figure 2B ). These data are consistent with the difference in Kaplan-Meier curve slopes and suggest that Hif1α haploinsufficiency, rather than expansion of HIF2α expression, reduces the incidence of thymic lymphoma in p53 H/H mice, allowing other types of tumors to be detected. Pathological findings are tabulated in Supplemental Figures 3-5 , and images of tumor types observed during pathological evaluation of p53 H/H mice are provided in Figure 4 and Supplemental Figure 1 . While these data were not the expected outcome of our experimental design, they suggested an important role for HIF1α in T-cell malignancy.
Age at presentation with thymic lymphomas is significantly increased in Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H mice In addition to decreased incidence of thymic lymphomas in Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H mice, the age at which these animals presented with tumors was also significantly increased ( Figure 5A ). This difference in latency could be caused by changes in tumor initiation or tumor growth rates. To determine if changes in proliferation rates contributed to altered onset of thymic lymphoma symptoms, we performed immunohistochemistry for the mitotic marker phospho-histone H3 (Ser10) on tumor sections ( Figure 5B ). However, no significant change in tumor mitotic index was observed. In contrast, TUNEL staining showed increased levels of apoptosis in both Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H tumors relative to controls ( Figure 5C ). Since all tumors were harvested after the mice became symptomatic, it is difficult to determine whether the proliferation and apoptosis rates observed in histological sections directly impact tumor progression. Figure 6A ). Since CD25 is a developmental marker whose expression is closely correlated with Notch activity during T-cell maturation, we hypothesized that differences in CD25 levels could correspond to differential Notch pathway activation among Hif1α +/+ p53 H/H , Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H tumors ( Figure 6C ). During normal T-cell differentiation, Notch1 expression is high at the β-selection checkpoint, when cells receiving appropriate signals through the T-cell receptor begin to proliferate rapidly ( Figure 6C ). These early stages of development also correspond to CD25 expression. The Notch pathway is then downregulated, cell division ceases, and T-cells continue to mature (27, 28) . Given that Notch1 is important for T-cell commitment and proliferation during β-selection, aberrant Notch1 expression after this stage could promote tumorigenesis. To assess Notch pathway activation in our study, we used QRT-PCR to measure mRNA levels of Deltex-1 (Dtx1) and Notch-regulated ankyrin repeat protein (Nrarp), two Notch transcriptional targets ( Figure 6A Notch mutations are common in mouse T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and occur in the PEST domain of Notch1, a region important for degradation of activated Notch (27) . To determine if Notch1 was mutated in our study, we sequenced the Notch1 PEST domain in the thymic lymphomas, but only found mutations in one tumor (n=16, data not shown). However, western blots of tumor lysates demonstrated increased stabilization of cleaved Notch1 in Hif1α +/+ p53 H/H tumors relative to most Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H samples ( Figure 6B ). Furthermore, Notch stabilization directly correlated with Dtx1 and Nrarp expression levels. Since Notch promotes T-cell lymphoma growth, decreased Notch activity in Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H tumors could contribute to the delayed presentation observed in these cohorts. These results suggest that HIF1α promotes the stability of activated Notch, thereby contributing to thymic lymphoma development ( Figure  6D ).
An alternate mechanism for Notch stabilization is deletion of the E3 ubiquitin ligase Fbw7 or upregulation of Notch ligands Jagged 1 (Jag1), Jag2, Delta-like-1 (Dll1), Dll3, or Dll4. However, we did not observe decreases in the expression of Fbw7 or any Notch ligands in our study (data not shown). Instead, it is probable that HIF1α is acting directly to promote Notch stability. Indeed, Gustafsson et al. recently demonstrated in neural and myogenic precursor cells that HIF1α can bind and stabilize activated Notch, promoting its transcriptional activity (29) .
Discussion
Xenograft experiments (9, 11, 12, 15) indicate that the HIFα subunits can have differential effects on tumor growth. To evaluate the relative contribution of each HIFα subunit in a more physiologic model of spontaneous tumorigenesis, we analyzed the effect of varying HIFα levels on tumor latency and spectrum in mice homozygous for the R270H mutation in p53. While p53 H/− and p53 H/+ mice were previously characterized by Olive et. al (19) , p53 H/H homozygotes have not been described. We found that p53 H/H mice developed substantially more thymic lymphomas than p53 H/− animals. Consistent with our observations in mice carrying the R270H mutation, Terzian et. al describe a very high incidence of lymphomas and sarcomas in p53 R172H/R172H mice when compared to heterozygotes for the R172H mutation (30) . p53 H/H mice also present with thymic lymphomas at a younger age. These observations suggest that, at least in thymocytes, the R270H mutant may actively promote tumorigenesis. One potential mechanism for this effect is the observation that p53 mutants disrupt DNA damage-response pathways (31) . Mutations in other DNA damage-response genes, such as H2ax and 53bp1, have also been shown to accelerate thymic lymphoma formation in a p53-null background, illustrating the importance of this pathway as a tumor suppressive mechanism in T-cells (32, 33) . Moreover, when activated, mutant p53 has the potential to accumulate to higher levels in p53 H/H thymocytes as compared to p53 H/− thymocytes. Excess stabilized mutant p53 may then promote lymphomagenesis. Of note, mutant p53, stabilized by deletion of MDM2, accelerates tumorigenesis and promotes metastasis in a dose dependent manner (30) . The decreased numbers of brain tumors and sarcomas observed in p53 H/H mice was likely to be a consequence of this shift towards increased numbers and earlier incidence of thymic lymphomas. Since mice die quickly from respiratory distress once thymic lymphomas have reached a threshold size, it may preclude their living long enough to succumb to other tumor types. The age at which mice had to be sacrificed for sarcomas is greater than that for thymic lymphomas (189 v. 117 days; Supplemental Figure 3) , suggesting that these tumors have a longer latency period. Because fewer p53 H/− mice developed thymic lymphomas, other tumor types could be observed. Using the p53 H/H mouse model, we then asked if expanded HIF2α expression could alter tumor spectrum or growth given that many human tumors express high levels of HIF2α. To our surprise, the Hif2α knock-in allele had no effect on any of these parameters. This result suggests either that HIF2α is not important for spontaneous tumorigenesis in the p53 H/H mouse model, or that HIF2α expression levels achieved in susceptible tissues were insufficient to promote tumor formation. There are also several important differences between the spontaneous tumors observed in p53 H/H mice and xenograft models used in previous studies (6, 19) . Increased HIF2α-mediated Tgf-α expression contributes to the growth of both renal clear cell tumors and ES cell-derived teratomas by activating epidermal growth factor receptor signaling; however, a role for this pathway in thymic lymphomas has not been described. Thus, the pro-growth pathways activated by HIF2α may not play an important role in lymphomagenesis, explaining why the Hif1α KI/+ allele did not promote thymic lymphoma formation in p53 H/H mice. It should also be noted that homozygous Hif1α KI/KI ES cells were used in previous subcutaneous tumor models, where the dosage of HIF2α achieved was significantly higher (6). Moreover, the incidence of teratomas in p53 H/H mice was low (only two were observed), so the impact of increased HIF2α expression on spontaneous teratoma formation cannot be adequately determined. The short latency period and limited spectrum of tumors observed in p53 H/H mice may also have precluded the detection of subtle HIF2α-mediated effects. A similar study was therefore conducted in p53 H/+ mice, which develop a wider spectrum of tumors, but the number of mice examined (n≈20) was not large enough to find significant changes in spectrum and latency.
To further study the role of HIF2α in spontaneous tumorigenesis, a conditional knockout model utilizing global, postnatal Hif2α deletion may be more valuable (8) . Similarly, conditional Hif1α deletion will be important to characterize its role at various stages of tumorigenesis, from initiation to growth and metastasis, as well as tissue-specific effects. These studies should reveal the aggregate impact of each of the α subunits on tumor promotion or suppression, clarifying potentially conflicting in vitro findings. For instance, while HIF1α acutely inhibits proliferation in response to hypoxia by inhibiting c-Myc activity, it also promotes tumor growth by increasing angiogenesis and reprogramming cell metabolism (1) . Inhibition of proliferation is likely to be a transient phenomenon that allows cells to adapt to hypoxic stress, and may not translate to reduced tumor growth in vivo. The impact of HIF1α on physiologic levels of cMyc is also different than its effect on overexpressed, oncogenic c-Myc (34) . Indeed, in a cMyc dependent B-cell lymphoma model, HIF1α promotes tumor growth (35) . Another important consideration is the difference between constitutive stabilization of the HIFα subunits, as occurs in VHL-deficient renal carcinomas, and more transient oxygen-regulated accumulation.
In p53 H/H mice, loss of one Hif1α allele significantly reduced the incidence of thymic lymphomas, thus uncovering an important role for HIF1α in thymic lymphomagenesis in vivo. In addition, the age at which these mice presented with thymic lymphomas was significantly increased by Hif1α haploinsufficiency, suggesting that tumor onset or tumor growth was delayed by decreasing levels of HIF1α. While thymic lymphomas observed in Hif1α +/− p53 H/H and Hif1α KI/+ p53 H/H mice exhibited similar proliferation rates, increased cell death was noted, indicating that HIF1α is important for the survival of thymocytes during tumor growth. To better understand mechanism(s) whereby HIF1α promotes thymic lymphomagenesis, we conducted an unbiased search for gene expression changes correlated with decreased HIF1α. Microarray analysis on thymic lymphoma mRNA from each genotype uncovered a dramatic decrease in CD25 expression, a marker for Notch pathway activity, in Notch pathway activation contributes significantly to the pathogenesis of acute T-ALL in both mice and humans (27) . Mouse models have demonstrated that constitutively activated Notch induces murine T-ALL (36) (37) (38) , and inhibition of Notch in mouse T-ALL cell lines causes cell death (25, 39) , suggesting that Notch is critical both for induction of leukemogenesis as well as for leukemic cell survival. In addition, overexpression of activated Notch1 is evident in human TALL, and is frequently due to mutations in Notch1 that lead to constitutive stabilization (25, 27, 40) . As stated above, activating Notch1 mutations have been observed in multiple mouse models of T-ALL and commonly occur in the PEST domain (26) . While we failed to detect Notch1 PEST domain mutations in most of our tumors, we did observe significantly increased expression of activated Notch1 and downstream Notch transcriptional targets in Hif1α +/+ p53 H/H tumors as compared to tumors deficient in Hif1α, implicating HIF1α in Notch pathway activation.
HIF1α has previously been proposed to increase the stability of activated Notch1 and to promote Notch target activation in myogenic and neural precursor cells (29) . However, a role for HIF1α in Notch-driven tumorigenesis had not been demonstrated. Here, we identify an important and novel role for HIF1α in thymic lymphoma development. Mice with normal HIF1α levels exhibit thymic lymphoma-associated morbidity earlier and at a substantially higher incidence than Hif1α heterozygous mice. In addition, the tumors exhibit less cell death and higher levels of activated Notch1 and Notch targets than thymic lymphomas arising in Hif1α heterozygous mice, implicating HIF1α in Notch pathway regulation during tumorigenesis. This study is also the first to characterize the phenotype of p53 H/H mice and, in doing so, provides further support for a gain-of-function effect of the R270H mutation.
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